trial to assess whether a reduced-dose regimen of apixaban (2.5 mg twice daily) would be noninferior to a full-dose regimen (5.0 mg twice daily) for the prevention of recurrent venous ...

One group received standard care, while the other got standard care plus apixaban (2.5 mg twice daily) for three months. After three months, the apixaban group had fewer clot recurrences—24% ...

Patients were randomized in a double-blind fashion to receive 2.5 mg or 5 mg apixaban (Eliquis; Bristol Myers Squibb) twice daily for 12 months. The median time between the index VTE and enrollment ...

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

Participants were randomized to oral apixaban at a reduced dose (2.5 mg) or a full dose (5.0 mg) twice daily for 12 months. The primary outcome was centrally adjudicated fatal or nonfatal ...